Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $34.13, but opened at $32.54. Dyne Therapeutics shares last traded at $32.17, with a volume of 260,922 shares.

Analyst Ratings Changes

DYN has been the topic of several research reports. Stifel Nicolaus boosted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Chardan Capital reissued a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday. Piper Sandler reissued an "overweight" rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. JPMorgan Chase & Co. cut Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Finally, StockNews.com cut Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $51.40.

Dyne Therapeutics Trading Down 11.2 %

The company has a fifty day moving average of $32.58 and a two-hundred day moving average of $35.08. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of -8.51 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the company's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. This represents a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. The trade was a 1.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 158,975 shares of company stock worth $5,693,789 over the last three months. Company insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. RA Capital Management L.P. acquired a new position in Dyne Therapeutics in the first quarter valued at about $140,666,000. FMR LLC increased its holdings in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after acquiring an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company's stock worth $75,915,000 after acquiring an additional 2,663,910 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Dyne Therapeutics by 8,284.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company's stock worth $32,141,000 after acquiring an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company's stock worth $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.